|
rs77375493
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Leukaemia</span> arising in a JAK2 V617F</span>-negative clone is TP53 independent and shows better survival.
|
28542718 |
2017 |
|
rs77375493
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In particular, gain-of-function mutations in the <i>JAK</i> genes, most frequently, V617F in the pseudokinase domain of JAK2, have been mapped in patients with blood disorders, including myeloproliferative neoplasms and leukemias.
|
29379470 |
2017 |
|
rs771138120
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Absence of R24C mutation of the CDK4 gene in leukemias and solid tumors.
|
12731669 |
2003 |
|
rs766274360
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Progression to secondary myelofibrosis/leukemia is influenced by exposure to cytoreductive agents, and caspase and BER polymorphisms {globally, CASP8 3'untranslated region [odds ratio (OR)=0.24; 95% confidence interval (CI), 0.08‑0.69], XRCC1 Arg194Trp [OR=3.58; 95% CI, 0.98‑13.01]; for essential thrombocythemia patients CASP9 Arg173His [OR=11.27; 95% CI, 1.13‑112.28], APEX1 Asp148Glu [OR=0.28; 95% CI, 0.74‑1.03], and XRCC1 Arg194Trp [OR=6.60; 95% CI, 1.60‑27.06]}.
|
30320340 |
2018 |
|
rs765669662
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In genomic DNAs prepared from 105 leukemia (n = 54) and non-leukemia (n = 51) specimens, PCR amplifications and direct sequencing of exon 3 identified a high-frequency G to A single nucleotide polymorphism at position 80 that resulted in a change of arginine-27 to histidine-27.
|
11705857 |
2001 |
|
rs765669662
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The allelic frequencies of G/A80 were nearly identical for the non-leukemia (42.2% CGC and 57.8% CAC) and leukemia (40.7% CGC and 59.3% CAC) genomic DNAs.
|
11705857 |
2001 |
|
rs762613037
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The bone marrow and/or peripheral blood from 126 patients with acute myeloid leukemia (AML), 57 with chronic myeloid leukemia (CML), 91 with acute lymphocytic leukemia (ALL), and 178 normal controls were analyzed using a polymerase chain reaction-restriction fragment length polymorphism (RFLP) assay to evaluate the association of the endostatin polymorphisms D104N (nucleotide 4349G --> A) with leukemia.
|
12693719 |
2003 |
|
rs75612255
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The luciferase reporter assay showed that among the six SNPs tested, the rs75612255 C allele and rs113017087 C allele in promoter 1A as well as the rs138386816 T allele and rs115658307 T allele in promoter 1B significantly increased luciferase activity in the human erythromyeloblastoid leukaemia cell line K562.
|
28105931 |
2016 |
|
rs754944509
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Thus, the aim of this study was to investigate the effects of Shb knockout on the development of leukemia in three additional models, that is, colony stimulating factor 3 receptor-T618I-induced neutrophilic leukemia, p190 Breakpoint cluster region-cAbl oncogene 1 tyrosine kinase-induced B-cell leukemia, and G12D-Kras-induced T-cell leukemia/thymic lymphoma.
|
29792386 |
2018 |
|
rs754894156
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The NQO1 rs1800566 (C609T), PON1 rs854560 (L55M), and PON1 rs662 (Q192R) polymorphisms modified risk depending on leukemia subtype (decreased in AML, increased and decreased in ALL, respectively), age strata, and variant genotype combinations.
|
22976839 |
2012 |
|
rs753000469
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Posterior column ataxia with retinitis pigmentosa coexisting with sensory-autonomic neuropathy and leukemia due to the homozygous p.Pro221Ser FLVCR1 mutation.
|
28766925 |
2017 |
|
rs749140677
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Recipient MTHFR polymorphisms (C677T) were associated with acute GvHD (P=0.03), and recipient VDR TaqI with TRM and overall survival (P=0.006 and P=0.04, respectively).Genetic factors that interfere with drug metabolisms are associated with treatment-related toxicities, GvHD and survival after HLA-identical HSCT in patients with leukemia and should be investigated prospectively.
|
19005482 |
2009 |
|
rs748843032
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Ponatinib-Induced Graft-versus-Host Disease/Graft-versus-Leukemia Effect in a Patient with Philadelphia-Positive Acute Lymphoblastic Leukemia without the T315I Mutation Relapsing after Allogeneic Transplant.
|
28810255 |
2017 |
|
rs748843032
|
|
|
0.030 |
GeneticVariation |
BEFREE |
KW-2449, a multikinase inhibitor of FLT3, ABL, ABL-T315I, and Aurora kinase, is under investigation to treat leukemia patients.
|
19541823 |
2009 |
|
rs748843032
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Given the fact that all AKIs fail to inhibit BCR/ABL harboring the 'gatekeeper' mutation T315I, we investigated the effects of AKIs in combination with the allosteric inhibitor GNF2 in Ph + leukemia.
|
22985168 |
2012 |
|
rs74315450
|
|
|
0.020 |
GeneticVariation |
BEFREE |
The first, carrying a missense R174Q mutation, which acts as a dominant-negative mutant, is associated with thrombocytopenia and leukemia, and the second, carrying a monoallelic gene deletion inducing a haploinsufficiency, presents only as thrombocytopenia.
|
25490895 |
2015 |
|
rs74315450
|
|
|
0.020 |
GeneticVariation |
BEFREE |
The NQO1 rs1800566 (C609T), PON1 rs854560 (L55M), and PON1 rs662 (Q192R) polymorphisms modified risk depending on leukemia subtype (decreased in AML, increased and decreased in ALL, respectively), age strata, and variant genotype combinations.
|
22976839 |
2012 |
|
rs727503094
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We successfully established a mouse model of human leukemia by transplanting bone marrow cells co-transfected with the K-ras (G12D) mutation and AML1/ETO fusion protein.
|
24480914 |
2014 |
|
rs7090445
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Genetic analyses revealed a novel heterozygous mutation in the ETS domain of <i>ETV6</i> (c.1136T>C, p.Leu379Pro) along with absence of heterozygosity of chromosome (10)(q21.2q21.3), yielding a biallelic leukaemia risk allele in <i>ARID5B</i> (rs7090445-C).
|
31704777 |
2019 |
|
rs6964823
|
|
|
0.010 |
GeneticVariation |
BEFREE |
It was found that the variants rs10740055 of ARID5B and rs6964823 of IKZF1 act individually and additively as risk factors in the development of leukemia in the populations of Jammu and Kashmir in Northern India.
|
30810385 |
2019 |
|
rs662
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The NQO1 rs1800566 (C609T), PON1 rs854560 (L55M), and PON1 rs662 (Q192R) polymorphisms modified risk depending on leukemia subtype (decreased in AML, increased and decreased in ALL, respectively), age strata, and variant genotype combinations.
|
22976839 |
2012 |
|
rs662
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The NQO1 rs1800566 (C609T), PON1 rs854560 (L55M), and PON1 rs662 (Q192R) polymorphisms modified risk depending on leukemia subtype (decreased in AML, increased and decreased in ALL, respectively), age strata, and variant genotype combinations.
|
22976839 |
2012 |
|
rs6413463
|
|
|
0.700 |
GeneticVariation |
UNIPROT |
|
|
|
|
rs61754966
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Among these, an association with cancer was found most frequently for 657del5 (in leukemia/lymphoma and breast cancer) and I171V (in leukemia, breast, head and neck and colorectal cancers); however, other studies gave contradictory results.
|
18606567 |
2008 |
|
rs61754966
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Positive associations have also been reported for leukaemia and larynx cancer suggesting that I171V could be a more general susceptibility factor for malignancies.
|
18049891 |
2008 |